Seema Ahuja

1 post

The matter of a journal's reputation

5 min read
Analysis Science Biocon Björn Brembs COVID-19 cytokine release syndrome Dinesh Thakur Drug Controller General of India Itolizumab Jammi Nagaraj Rao journal impact factor Kiran Mazumdar-Shaw Newslaundry phase II clinical trials phase III clinical trials prestige journals prestigious journals reputed journals Seema Ahuja Sundar Ramanan The Telegraph

Apparently (and surprisingly) The Telegraph didn’t allow Dinesh Thakur to respond to an article by Biocon employee Sundar Ramanan, in which Ramanan deems Thakur’s article about the claims to efficacy…